Published December 2021 | Version v1
Journal article

Integrated Positron Emission Tomography/Magnetic Resonance Imaging in clinical diagnosis of Alzheimer's disease

Creators

  • 1. Key Laboratory for Experimental Teratology of the Ministry of Education and Center for Experimental Nuclear Medicine, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012 (China)

Description

Highlights: • Alzheimer's disease (AD) is the most common etiology of senile dementia. • PET/MRI has broad prospect of application in the early diagnosis of AD. • Advantages of PET/MRI and prospects in AD clinical diagnosis are introduced in this review. Alzheimer's disease (AD), a progressive neurodegenerative disease which seriously endangers the health of the aged, is the most common etiology of senile dementia. With the increasing progress of neuroimaging technology, more and more imaging methods have been applied to study Alzheimer's disease. The emergence of integrated PET/MRI (Positron Emission Tomography/Magnetic Resonance Imaging) is a major advance in multimodal molecular imaging with many advantages on the structure of resolution and contrast of image over computed tomography (CT), PET and MRI. PET/MRI is now used stepwise in neurodegenerative diseases, and also has broad prospect of application in the early diagnosis of AD. In this review, we emphatically introduce the imaging advances of AD including functional imaging and molecular imaging, the advantages of PET/MRI over other imaging methods and prospects of PET/MRI in AD clinical diagnosis, especially in early diagnosis, clinical assessment and prediction on AD.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ejrad.2021.110017

Additional details

Identifiers

DOI
10.1016/j.ejrad.2021.110017;
PII
S0720048X21004988;

Publishing Information

Journal Title
European Journal of Radiology
Journal Volume
145
Journal Page Range
vp.
ISSN
0720-048X
CODEN
EJRADR

Optional Information

Copyright
Copyright (c) 2021 Elsevier B.V. All rights reserved.